A Treatment Protocol for Expanded Access Administration of Prometic Plasminogen Due to Closure of Clinical Trial
- Conditions
- Hypoplasminogenemia
- First Posted Date
- 2018-08-22
- Last Posted Date
- 2022-12-09
- Lead Sponsor
- Prometic Biotherapeutics, Inc.
- Registration Number
- NCT03642691
- Locations
- ๐บ๐ธ
Indiana Hemophilia and Thrombosis Center, Indianapolis, Indiana, United States
๐บ๐ธTower Hematology and Oncology, Beverly Hills, California, United States
๐บ๐ธVanderbilt University Medical Center, Nashville, Tennessee, United States
A Single-patient Study of Repeat-dose Administration of Prometic Plasminogen (Human) Intravenous
- Conditions
- Hypoplasminogenemia
- First Posted Date
- 2017-08-29
- Last Posted Date
- 2020-04-24
- Lead Sponsor
- Prometic Biotherapeutics, Inc.
- Registration Number
- NCT03265171
A Study of Prometic Plasminogen IV Infusion in Subjects With Hypoplasminogenemia
Phase 2
Completed
- Conditions
- HypoplasminogenemiaCongenital Plasminogen Deficiency
- Interventions
- Biological: Plasminogen (Human) intravenous
- First Posted Date
- 2016-02-24
- Last Posted Date
- 2021-08-02
- Lead Sponsor
- Prometic Biotherapeutics, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT02690714
- Locations
- ๐ณ๐ด
Oslo University Hospital HF, Oslo, Sognsvannvejen 20, Norway
๐บ๐ธIndiana Hemophilia and Thrombosis Center, Indianapolis, Indiana, United States
A Phase 1 Study of ProMetic Plasminogen (Human) Intravenous in Adults and Children With Plasminogen Deficiency
Phase 1
Completed
- Conditions
- Type I Plasminogen DeficiencyHypoplasminogenemia
- Interventions
- Biological: Plasminogen (Human) Intravenous
- First Posted Date
- 2014-12-09
- Last Posted Date
- 2017-08-29
- Lead Sponsor
- Prometic Biotherapeutics, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT02312180
- Locations
- ๐บ๐ธ
Indiana Hemophilia and Thrombosis Center, Indianapolis, Indiana, United States
Study of ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10%
Phase 3
Completed
- Conditions
- Primary Immunodeficiency
- Interventions
- Biological: Prometic's Immune Globulin Intravenous 10%Biological: Immune Globulin Intravenous
- First Posted Date
- 2014-10-20
- Last Posted Date
- 2021-11-05
- Lead Sponsor
- Prometic Biotherapeutics, Inc.
- Target Recruit Count
- 82
- Registration Number
- NCT02269163
- Locations
- ๐บ๐ธ
Allergy Associates of the Palm Beaches, North Palm Beach, Florida, United States
๐บ๐ธImmunoe International Research, Centennial, Colorado, United States
๐บ๐ธJohns Hopkins All Children's Hospital, Saint Petersburg, Florida, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath